Methods

The design, baseline characteristics, and primary results of this institutional review board–approved trial are published. 1, 2 In brief, PARADISE-MI was a double-blind, active-controlled randomized, clinical trial that compared sacubitril/valsartan with ramipril in 5661 patients with written informed consent, an acute myocardial infarction (within 0.5–7 days of presentation) with either left ventricular ejection fraction≤ 40% or transient pulmonary congestion. Previous heart failure or clinical instability (requiring intravenous diuretics, inotropes, or blood pressure support within the 24 hours before randomization) were major exclusions, and all patients provided written informed consent.